This study firstly reported the treatment outcome of a locally advanced unresectable NSCLC patient with a rare complex EGFR <i>p.</i>G719X/<i>p.</i>S768I mutations who received befotertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.